[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100440058":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":51,"collaborators":33,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":33,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":33,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":33,"overallStatus":37,"whyStopped":33,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University of Copenhagen","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Healthy control subjects","EXPERIMENTAL","Healthy control subjects undergoing a hyperinsulinemic euglycemic clamp",[13],"Drug: Insulin",{"label":15,"type":10,"description":16,"interventionNames":17},"Breast cancer survivors","Breast cancer survivors undergoing a hyperinsulinemic euglycemic clamp",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Insulin","Hyperinsulinemic euglycemic clamp",[15,9],[22],[26],{"name":27,"affiliation":5,"role":28},"Lykke Sylow, PhD","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":33,"email":34},"CONTACT","20955250",null,"Lykkesylow@sund.ku.dk",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":39,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Copenhagen","DK","2100","Denmark",{"type":43,"coordinates":44},"Point",[45,46],12.56553,55.67594,{"lat":46,"lon":45},[49],{"name":27,"role":31,"phone":50,"phoneExt":33,"email":34},"0045 20955250",{"type":28,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"Lykke Sylow","Associate Professor","100440058","insulin-sensitivity-after-breast-cancer-100440058",false,"NCT05010356","Insulin Sensitivity After Breast Cancer","Study of Molecular Causes of Metabolic Disorders in Obese Premenopausal Women After Breast Cancer","Inclusion Criteria:\n\n* Premenopausal women operated for breast cancer and after completing adjuvant chemotherapy and no earlier than 3 weeks after its termination\n* BMI: 25-30\n* Healthy controls will be included matched by gender, weight, age, and level of physical activity to the patient group included as subjects\n\nExclusion Criteria:\n\n* Known postmenopause occurred at the time of diagnosis of breast cancer\n* Alcohol intake of\\> 7 items \u002F week\n* Smoker\n* Already known Type 2 diabetes mellitus or metabolic syndrome and medical treatment thereof.\n* Cardiovascular disease and its medical treatment\n* Impaired mobility",true,"FEMALE","20 Years","45 Years",{"count":66,"type":67},24,"ESTIMATED","INTERVENTIONAL",[70],"NA","Epidemiological studies have revealed that 60-80% of women with breast cancer (BC) develop metabolic disorders that are similar to those observed in conditions like type 2 diabetes. These metabolic disorders, including insulin resistance, obesity, hyperinsulinemia, and glucose intolerance, are associated with increased BC recurrence and mortality. Skeletal muscle is the major site of glucose uptake in humans. The aims of the present project are to 1) determine the involvement of insulin resistance in skeletal muscle in the metabolic disorders prevalent in BC survivors, 2) identify BC-and\u002For treatment-induced molecular changes in skeletal muscle from BC survivors .",[73,74,75,76],"Insulin Sensitivity\u002FResistance","Breast Cancer","Survivorship","Metabolic Disturbance","2021-08-10",{"date":79,"type":80},"2021-08-18","ACTUAL",{"date":82,"type":67},"2021-08",{"date":84,"type":67},"2026-09",{"name":5,"class":6},1]